Dr. Deb Schrag, MD, MPH, is among the respected medical oncologists and public health heads for care and research at the gastrointestinal clinical oncology level. In fact, her June 2021 elevation to the Chair of the Department of Medicine at MSK only validated her high stature within the clinical and academic leadership space. Dr. Schrag obtained an M.D. from Columbia University and then became an intern in internal medicine at Brigham and Women's Hospital. Following this, she became a fellow, after internship, in medical oncology at the Dana-Farber Cancer Institute. Subsequently, Dr. Schrag completed a postdoctoral fellowship in Health Services Research at Harvard School of Public Health, and also earned a Master of Public Health degree there. Dr. Schrag was a senior leader at Dana-Farber in clinical data governance and cancer care delivery research. She contributed remarkably to the mentorship of many fellows in initiating and leading a fellowship training program in population sciences. Perhaps, most significantly, it is in the area of quality and delivery of care for those afflicted with cancer that Dr. Schrag's innovative work prevails. Her innovatory views on the delivery of care have come to be instrumental in changing the character of the relationship between the clinicians and their patients, and its interaction in making decisions about the treatments. Most prominently among her influential contributions, she led the clinical trial PROSPECT, which really challenged thinking that locally advanced rectal cancer could never be managed without radiation therapy. With over 1,100 patients enrolled, it proved that chemotherapy alone could work fine in treating cases of rectal cancer, without needing radiation therapy before surgery. Data from this trial could significantly reduce the burden of side effects due to radiation and increase quality of life for many patients, particularly young patients who are concerned for their fertility and long-term health potential. Dr. Schrag is one of the most outstanding figures in medical science and practice, thanks to her efforts in improvement aimed at improving the care and results of patients in the field of oncology. Her work pushes forward not only the science of how best to treat cancer but also pays equal emphasis on patient-centered care—making sure the voices and experiences of patients are an essential part of developing new therapies.